Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan's National Cancer Center has agreed to form a research alliance with Daiichi Sankyo for the development of anticancer agents utilizing the research capabilities of both organizations.
Subscribe to our email newsletter
As per the alliance, the high-level cancer research technology and clinical experience of the National Cancer Center will be integrated with the advanced research and drug discovery capabilities of Daiichi Sankyo.
The National Cancer Center will present Daiichi Sankyo with research results in line with Daiichi Sankyo’s research and drug discovery policy and promote "Exploratory Research for Drug Target Identification or "Early Drug Discovery Research".
The Exploratory Research for Drug Target Identification will include exploration, identification, and evaluation of drug targets.
Under the Early Drug Discovery Research, Daiichi Sankyo will work to acquire drug candidate compounds and antibodies through high-throughput screening.